Benefits
Tooth surface stain removal toothpaste 8-week RCT (PMID 29178760)
70 adults with extrinsic tooth staining randomized to lysozyme toothpaste vs control for 8 weeks (parallel-controlled double-blind). Lysozyme toothpaste effective in REMOVING extrinsic stains from tooth surface. Foundational extrinsic stain removal evidence.
Gingival inflammation reduction CELC RCT (PMC6407240 KCT0001366)
Multicenter randomized double-blind placebo-controlled trial in chronic periodontitis. CELC (vitamin C + E + LYSOZYME + carbazochrome, IGATAN F® Myung-In) for 8 weeks. GEE model (adjusted age/gender/visits): test group showed 2.5× GI improvement vs control (P=0.022). Significant gingival inflammation reduction. Foundational periodontitis evidence.
Multi-enzyme lozenge plaque control 7-day RCT
24 healthy adults randomized to multi-enzyme lozenge (Active n=12) or placebo (n=12). 1 lozenge TID for 7 days; no oral hygiene allowed. TM-QHPI plaque index + Gingival Index + 16S rRNA. Pilot evidence for multiple plaque-matrix degrading enzymes including lysozyme as non-biocidal plaque control approach. ALL subjects completed; no AEs.
Peptidoglycan hydrolysis mechanism
Lysozyme HYDROLYZES the linkage between N-acetylmuramic acid + N-acetylglucosamine of PEPTIDOGLYCAN in cell wall of GRAM-POSITIVE bacteria — effectively limiting growth. Foundational antimicrobial mechanism distinguishing from lactoperoxidase hypothiocyanite system.
Toothpaste enzyme + protein synergy (PMID 30696552 13-week)
13-week RCT (n=229 completed) — toothpaste with three-enzyme system (amyloglucosidase + glucose oxidase + LPO) + LYSOZYME + lactoferrin showed significant plaque + gingival benefit vs commercial control. Test group plaque + gingival scores fell while control group rose. Foundational multi-component synergy evidence.
In vivo salivary defense enhancement
PMC12581499 mechanism — toothpaste containing enzymes + proteins ENHANCES salivary defenses by INCREASING in vivo levels of antimicrobial compounds LYSOZYME + hydrogen peroxide. Mechanism: supplementation reinforces natural saliva antimicrobial system.
Lysozyme + LPO synergy (Streptococcus mutans inhibition)
Lenander-Lumikari 1992 (J Dent Res 71:484-490) — LYSOZYME ENHANCES inhibitory effects of peroxidase system on glucose metabolism of STREPTOCOCCUS MUTANS. Mechanism: lysozyme + LPO synergy against cariogenic bacteria. Distinguishing combined antimicrobial mechanism.
Mechanism of action
Peptidoglycan hydrolysis (gram-positive cell wall)
Hydrolyzes N-acetylmuramic acid + N-acetylglucosamine linkage of peptidoglycan — disrupts gram-positive bacterial cell wall integrity. Foundational antimicrobial mechanism.
Lysozyme + LPO antimicrobial synergy
Synergistic with lactoperoxidase against S. mutans (Lenander-Lumikari 1992 J Dent Res). Mechanism: combined peptidoglycan + hypothiocyanite attack on cariogenic bacteria.
Salivary defense system component
Natural human saliva contains lysozyme — endogenous antimicrobial defense. Topical/oral supplementation enhances natural mechanism, particularly valuable in xerostomia/periodontitis populations.
Plaque-matrix degradation (non-biocidal)
Multi-enzyme lozenge mechanism — degrades plaque matrix without biocidal activity. Distinguishing approach preserving oral microbiome diversity.
Anti-inflammatory effects (gingival)
PMC6407240 CELC RCT — 2.5× GI improvement supports anti-inflammatory effect via gingival pathogen reduction + matrix degradation.
Tooth stain removal mechanism
PMID 29178760 — extrinsic stain removal mechanism. Likely via plaque pellicle degradation + bacterial removal.
Clinical trials
Randomized parallel-controlled double-blind clinical trial.
70 adults with extrinsic tooth staining. Lysozyme toothpaste vs control for 8 weeks.
Lysozyme toothpaste effective in REMOVING extrinsic stains from tooth surface. Safety profile favorable. Foundational stain removal evidence supporting oral hygiene applications.
Multicenter randomized double-blind placebo-controlled trial (KCT0001366, retrospectively registered Jan 2015). Approved by IRB at Kyung Hee University Dental Hospital + Yonsei University Hospital + Dankook University Hospital.
Chronic periodontitis patients. Stratified block randomization. CELC (vitamin C + E + LYSOZYME + carbazochrome, IGATAN F® Myung-In) for 8 weeks vs placebo. GEE model adjusted for age, gender, visits.
Test group showed 2.5× GI (Gingival Index) improvement vs control (P=0.022). Significant reduction in gingival inflammation. Other parameters similar between groups. Foundational chronic periodontitis evidence with fixed-dose combination including lysozyme.
Randomized controlled pilot trial (ScienceDirect S0300571224002768 2024).
24 healthy adults randomized to Active (n=12) or Placebo (n=12). 1 lozenge TID for 7 days; no oral hygiene procedures allowed. TM-QHPI plaque index + Gingival Index + 16S rRNA gene sequencing of plaque + saliva at baseline + 7 days.
All 24 subjects completed study; NO adverse events. Pilot evidence for multiple plaque-matrix degrading enzymes (including lysozyme) as non-biocidal plaque control approach. Foundational multi-enzyme lozenge mechanism evidence.
About this ingredient
LYSOZYME (muramidase) is a SALIVARY GLYCOSIDE HYDROLASE EC 3.2.1.17 that hydrolyzes N-acetylmuramic acid + N-acetylglucosamine peptidoglycan linkages of GRAM-POSITIVE BACTERIAL CELL WALLS. Component of natural human saliva antimicrobial defense system. Commercial lysozyme: bovine + hen egg white sources. PIVOTAL CLINICAL EVIDENCE: PMID 29178760 — 70-adult 8-week parallel-controlled double-blind RCT of lysozyme toothpaste for extrinsic tooth stain removal (effective). PMC6407240 KCT0001366 — multicenter randomized double-blind placebo-controlled trial in chronic periodontitis. CELC (vit C + E + LYSOZYME + carbazochrome, IGATAN F® Myung-In) for 8 weeks. GEE model: 2.5× GI improvement vs control (P=0.022). Multi-enzyme lozenge 24-pt 7-day pilot (ScienceDirect 2024) — Active vs placebo lozenge TID, no oral hygiene allowed; all completed, no AEs. PMID 30696552 13-week toothpaste enzyme+protein RCT (n=229) including lysozyme + lactoferrin + LPO + amyloglucosidase + glucose oxidase showed significant plaque + gingival benefit. PMC12581499 mechanism — toothpaste enzyme+protein system enhances in vivo salivary lysozyme + H2O2 levels. LENANDER-LUMIKARI 1992 (J Dent Res 71:484-490) — LYSOZYME + LPO synergy against S. mutans glucose metabolism.
MECHANISMS: PEPTIDOGLYCAN HYDROLYSIS (gram-positive cell wall — distinguishing antimicrobial); LYSOZYME + LPO synergy against cariogenic bacteria; SALIVARY DEFENSE component reinforcement; PLAQUE-MATRIX degradation (non-biocidal preserving oral microbiome); ANTI-INFLAMMATORY effects (CELC GI improvement); TOOTH STAIN REMOVAL via plaque pellicle degradation. EVIDENCE: 3/5 reflects: (1) PMID 29178760 70-pt 8-week stain RCT, (2) PMC6407240 KCT0001366 chronic periodontitis multicenter 8-week RCT (2.5× GI improvement), (3) 24-pt enzyme lozenge 7-day pilot, (4) PMID 30696552 13-week toothpaste 229-pt RCT with lysozyme component, (5) PMC12581499 in vivo salivary defense mechanism, (6) LENANDER-LUMIKARI 1992 lysozyme + LPO synergy mechanism, (7) WELL-CHARACTERIZED peptidoglycan hydrolysis mechanism, (8) NATURAL SALIVA component reinforcement framework, (9) HONEST limitation: most evidence in multi-component formulations, (10) higher-evidence than typical 'oral health enzyme' due to multi-RCT methodology + multi-component synergy. SAFETY: Excellent — topical/oral natural enzyme + multiple multi-week trials. Best positioned as: (a) GINGIVITIS / CHRONIC PERIODONTITIS adjunct (CELC PMC6407240 evidence), (b) DENTAL PLAQUE control adjunct, (c) TOOTH SURFACE STAIN removal (PMID 29178760), (d) SALIVARY DEFENSE ENHANCEMENT (xerostomia, periodontitis), (e) MULTI-ENZYME formulations preferred (lysozyme + LPO + lactoferrin synergy), (f) PREGNANCY: toothpaste application generally safe, (g) EGG/BOVINE allergies: caution (source-dependent), (h) higher-evidence than typical oral enzyme due to multi-RCT + mechanism evidence. Honest framing: Lysozyme is a foundational salivary antimicrobial enzyme with solid evidence as oral health adjunct — PMID 29178760 stain removal + PMC6407240 CELC chronic periodontitis (2.5× GI improvement) + 24-pt enzyme lozenge pilot + PMID 30696552 13-week toothpaste 229-pt RCT support clinical applications. Lysozyme + LPO synergy (Lenander-Lumikari 1992) is biochemically distinguishing — peptidoglycan + hypothiocyanite combined attack. Most evidence in MULTI-COMPONENT formulations (lysozyme typically combined with LPO + lactoferrin + amyloglucosidase + glucose oxidase) — isolated lysozyme efficacy harder to establish. Reasonable oral health adjunct based on multi-RCT evidence with peptidoglycan hydrolysis mechanism — particularly compelling for those with chronic periodontitis or seeking natural-saliva-replicating enzyme system.